Alembic Total Assets vs Total Cash From Operating Activities Analysis

APLLTD Stock

1,081 7.20 0.66%

Alembic Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alembic Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alembic Pharmaceuticals is a good investment. Please check the relationship between Alembic Pharmaceuticals Total Assets and its Total Cash From Operating Activities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alembic Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Total Assets vs Total Cash From Operating Activities

Total Assets vs Total Cash From Operating Activities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alembic Pharmaceuticals Total Assets account and Total Cash From Operating Activities. At this time, the significance of the direction appears to have strong relationship.

The correlation between Alembic Pharmaceuticals' Total Assets and Total Cash From Operating Activities is 0.69. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Cash From Operating Activities in the same time period over historical financial statements of Alembic Pharmaceuticals Limited, assuming nothing else is changed. The correlation between historical values of Alembic Pharmaceuticals' Total Assets and Total Cash From Operating Activities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Alembic Pharmaceuticals Limited are associated (or correlated) with its Total Cash From Operating Activities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Cash From Operating Activities has no effect on the direction of Total Assets i.e., Alembic Pharmaceuticals' Total Assets and Total Cash From Operating Activities go up and down completely randomly.

Correlation Coefficient

0.69

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Assets

Total assets refers to the total amount of Alembic Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Alembic Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Cash From Operating Activities

Most indicators from Alembic Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alembic Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alembic Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

As of November 29, 2024, Selling General Administrative is expected to decline to about 1.4 B. In addition to that, Tax Provision is expected to decline to about 152 M

	2021	2022	2023	2024 (projected)
Interest Expense	177.3M	501.7M	561.9M	590.0M
Depreciation And Amortization	2.9B	2.8B	2.7B	2.9B

Interest Expense Depreciation And Amortization

Alembic Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Retained Earnings	Accounts Payable	Short Term Debt	Net Receivables	Other Liab	Net Tangible Assets
Total Assets		0.64	0.27	0.95	0.98	0.99	0.59	0.11	0.99	0.14	0.25	0.49	0.4	0.99	-0.04	0.07	0.86	0.98	0.51	-0.06	0.76	0.77	0.8	0.78	0.85	0.86
Short Long Term Debt Total	0.64		0.13	0.78	0.48	0.65	0.97	-0.05	0.67	-0.09	-0.02	0.04	0.9	0.54	-0.31	-0.62	0.93	0.58	0.04	-0.03	0.31	0.45	0.89	0.72	0.38	0.38
Other Current Liab	0.27	0.13		0.2	0.25	0.27	0.16	-0.15	0.27	0.14	-0.07	0.15	0.28	0.22	0.19	0.38	0.26	0.26	0.16	-0.53	0.13	0.12	-0.02	0.19	0.19	0.22
Total Current Liabilities	0.95	0.78	0.2		0.88	0.94	0.72	0.13	0.94	0.14	0.19	0.39	0.5	0.91	-0.16	-0.16	0.94	0.94	0.4	0.02	0.7	0.68	0.91	0.86	0.78	0.77
Total Stockholder Equity	0.98	0.48	0.25	0.88		0.97	0.44	0.11	0.97	0.17	0.28	0.55	0.23	0.99	0.05	0.23	0.75	0.97	0.58	-0.07	0.79	0.78	0.69	0.69	0.86	0.89
Property Plant And Equipment Net	0.99	0.65	0.27	0.94	0.97		0.62	0.05	1.0	0.1	0.21	0.45	0.41	0.97	0.0	0.08	0.86	0.96	0.47	-0.05	0.73	0.77	0.8	0.73	0.81	0.84
Net Debt	0.59	0.97	0.16	0.72	0.44	0.62		-0.27	0.63	-0.04	-0.23	0.04	0.88	0.49	-0.16	-0.6	0.88	0.52	0.04	-0.14	0.29	0.47	0.85	0.67	0.27	0.34
Cash	0.11	-0.05	-0.15	0.13	0.11	0.05	-0.27		0.06	-0.17	0.92	0.02	-0.05	0.1	-0.62	0.03	0.08	0.18	0.01	0.48	0.03	-0.16	0.0	0.11	0.4	0.08
Non Current Assets Total	0.99	0.67	0.27	0.94	0.97	1.0	0.63	0.06		0.1	0.23	0.43	0.43	0.97	-0.01	0.06	0.87	0.95	0.46	-0.03	0.72	0.76	0.8	0.73	0.81	0.83
Non Currrent Assets Other	0.14	-0.09	0.14	0.14	0.17	0.1	-0.04	-0.17	0.1		-0.23	0.78	-0.18	0.21	0.12	0.05	0.04	0.21	0.76	-0.4	0.62	0.32	0.05	0.28	0.28	0.49
Cash And Short Term Investments	0.25	-0.02	-0.07	0.19	0.28	0.21	-0.23	0.92	0.23	-0.23		0.03	-0.01	0.24	-0.4	0.18	0.14	0.29	0.05	0.43	0.12	-0.01	-0.01	0.04	0.46	0.21
Common Stock Shares Outstanding	0.49	0.04	0.15	0.39	0.55	0.45	0.04	0.02	0.43	0.78	0.03		-0.13	0.59	0.08	0.17	0.24	0.57	1.0	-0.48	0.83	0.67	0.26	0.48	0.57	0.76
Non Current Liabilities Total	0.4	0.9	0.28	0.5	0.23	0.41	0.88	-0.05	0.43	-0.18	-0.01	-0.13		0.26	-0.37	-0.61	0.76	0.32	-0.13	-0.11	0.05	0.21	0.6	0.51	0.18	0.13
Inventory	0.99	0.54	0.22	0.91	0.99	0.97	0.49	0.1	0.97	0.21	0.24	0.59	0.26		0.0	0.14	0.78	0.99	0.61	-0.09	0.82	0.81	0.75	0.76	0.87	0.9
Other Current Assets	-0.04	-0.31	0.19	-0.16	0.05	0.0	-0.16	-0.62	-0.01	0.12	-0.4	0.08	-0.37	0.0		0.4	-0.27	-0.1	0.1	-0.28	0.07	0.13	-0.21	-0.42	-0.36	0.03
Other Stockholder Equity	0.07	-0.62	0.38	-0.16	0.23	0.08	-0.6	0.03	0.06	0.05	0.18	0.17	-0.61	0.14	0.4		-0.36	0.09	0.2	-0.19	0.15	0.14	-0.44	-0.26	0.22	0.23
Total Liab	0.86	0.93	0.26	0.94	0.75	0.86	0.88	0.08	0.87	0.04	0.14	0.24	0.76	0.78	-0.27	-0.36		0.83	0.25	-0.03	0.54	0.59	0.91	0.84	0.65	0.62
Total Current Assets	0.98	0.58	0.26	0.94	0.97	0.96	0.52	0.18	0.95	0.21	0.29	0.57	0.32	0.99	-0.1	0.09	0.83		0.59	-0.1	0.81	0.77	0.77	0.83	0.9	0.88
Common Stock	0.51	0.04	0.16	0.4	0.58	0.47	0.04	0.01	0.46	0.76	0.05	1.0	-0.13	0.61	0.1	0.2	0.25	0.59		-0.48	0.84	0.69	0.26	0.46	0.58	0.78
Current Deferred Revenue	-0.06	-0.03	-0.53	0.02	-0.07	-0.05	-0.14	0.48	-0.03	-0.4	0.43	-0.48	-0.11	-0.09	-0.28	-0.19	-0.03	-0.1	-0.48		-0.33	-0.49	0.02	-0.18	0.0	-0.29
Retained Earnings	0.76	0.31	0.13	0.7	0.79	0.73	0.29	0.03	0.72	0.62	0.12	0.83	0.05	0.82	0.07	0.15	0.54	0.81	0.84	-0.33		0.85	0.57	0.67	0.74	0.97
Accounts Payable	0.77	0.45	0.12	0.68	0.78	0.77	0.47	-0.16	0.76	0.32	-0.01	0.67	0.21	0.81	0.13	0.14	0.59	0.77	0.69	-0.49	0.85		0.64	0.62	0.63	0.89
Short Term Debt	0.8	0.89	-0.02	0.91	0.69	0.8	0.85	0.0	0.8	0.05	-0.01	0.26	0.6	0.75	-0.21	-0.44	0.91	0.77	0.26	0.02	0.57	0.64		0.83	0.56	0.61
Net Receivables	0.78	0.72	0.19	0.86	0.69	0.73	0.67	0.11	0.73	0.28	0.04	0.48	0.51	0.76	-0.42	-0.26	0.84	0.83	0.46	-0.18	0.67	0.62	0.83		0.77	0.67
Other Liab	0.85	0.38	0.19	0.78	0.86	0.81	0.27	0.4	0.81	0.28	0.46	0.57	0.18	0.87	-0.36	0.22	0.65	0.9	0.58	0.0	0.74	0.63	0.56	0.77		0.82
Net Tangible Assets	0.86	0.38	0.22	0.77	0.89	0.84	0.34	0.08	0.83	0.49	0.21	0.76	0.13	0.9	0.03	0.23	0.62	0.88	0.78	-0.29	0.97	0.89	0.61	0.67	0.82

Click cells to compare fundamentals

Alembic Pharmaceuticals Account Relationship Matchups

Alembic Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	59.9B	67.1B	71.2B	61.8B	64.5B	40.9B
Short Long Term Debt Total	18.3B	5.8B	7.2B	7.2B	5.1B	5.9B
Other Current Liab	418.9M	2.7B	3.0B	855.4M	2.7B	1.8B
Total Current Liabilities	17.5B	12.8B	17.2B	16.4B	14.6B	11.2B
Total Stockholder Equity	32.2B	51.3B	52.4B	43.7B	48.2B	26.7B
Property Plant And Equipment Net	31.0B	36.5B	39.5B	30.0B	30.7B	19.7B
Net Debt	17.6B	4.9B	6.6B	6.5B	3.9B	4.8B
Cash	718.4M	980.6M	610.9M	754.8M	1.2B	1.1B
Non Current Assets Total	35.3B	41.3B	42.6B	32.7B	33.7B	22.1B
Cash And Short Term Investments	718.4M	2.9B	610.9M	921.2M	1.2B	1.3B
Liabilities And Stockholders Equity	59.9B	67.1B	71.2B	61.8B	64.5B	40.9B
Non Current Liabilities Total	10.5B	3.6B	1.7B	1.8B	1.7B	3.2B
Inventory	11.9B	14.9B	16.1B	14.8B	16.4B	9.2B
Other Current Assets	200K	5.3B	3.8B	3.1B	2.9B	2.2B
Other Stockholder Equity	(31.1B)	27.0B	26.4B	7.5B	7.5B	5.6B
Total Liab	28.0B	16.4B	18.8B	18.1B	16.3B	14.3B
Total Current Assets	24.6B	25.8B	28.6B	29.1B	30.8B	18.9B
Accumulated Other Comprehensive Income	(5.0B)	18.5B	18.8B	335.4M	32.4M	30.8M
Current Deferred Revenue	2.1B	3.0B	3.7B	2.2B	(322.4M)	(306.3M)
Retained Earnings	15.4B	24.2B	25.5B	35.7B	40.3B	42.3B
Accounts Payable	6.3B	6.7B	7.1B	6.8B	7.4B	7.7B
Short Term Debt	8.7B	3.1B	6.4B	6.5B	4.5B	3.9B
Net Receivables	12.0B	3.5B	8.1B	10.5B	10.2B	7.0B
Other Liab	708M	867.1M	897.4M	958.1M	1.1B	847.2M
Net Tangible Assets	24.5B	29.2B	48.0B	50.8B	58.5B	61.4B
Other Assets	(1.7M)	1.1B	1.1B	1.2B	1.4B	1.5B
Short Long Term Debt	8.6B	200K	6.3B	6.4B	4.3B	3.8B
Property Plant Equipment	31.0B	36.5B	39.5B	30.0B	34.5B	23.0B
Long Term Debt Total	8.9B	2.7B	721.4M	692.3M	623.1M	591.9M
Intangible Assets	1.6B	2.7B	3.0B	3.2B	1.5B	0.0
Net Invested Capital	49.7B	53.3B	58.7B	50.1B	52.5B	52.2B
Net Working Capital	7.1B	13.0B	10.6B	12.7B	16.2B	11.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in Alembic Stock

Balance Sheet is a snapshot of the financial position of Alembic Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Alembic Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Alembic Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Alembic currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alembic Total Assets vs Total Cash From Operating Activities Analysis

Total Assets vs Total Cash From Operating Activities

Total Assets vs Total Cash From Operating Activities Correlation Analysis

Correlation Coefficient

Total Assets

Total Cash From Operating Activities

Alembic Pharmaceuticals fundamental ratios Correlations

Alembic Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alembic Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Alembic Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Shares Outstanding
Property Plant And Equipment Net	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Inventory	+ 0.99	Total Assets
Inventory	+ 0.99	Total Stockholder Equity

Other Current Assets	- 0.62	Cash
Other Stockholder Equity	- 0.62	Short Long Term Debt Total
Other Stockholder Equity	- 0.61	Non Current Liabilities Total
Other Stockholder Equity	- 0.6	Net Debt
Current Deferred Revenue	- 0.53	Other Current Liab
Accounts Payable	- 0.49	Current Deferred Revenue